Differentiating Retrocochlear from Cochlear Deafness

Clinical Features and Diagnostic Testing

The American Academy of Otolaryngology-Head and Neck Surgery states that no clinical features can reliably distinguish retrocochlear from cochlear causes of hearing loss 2, 3, 4
Tinnitus in the affected ear prior to hearing loss onset, associated otalgia, or paresthesias are more common in vestibular schwannoma, but these symptoms are too rare for their absence to rule out retrocochlear pathology 2, 4
All audiometric patterns have been documented in patients with vestibular schwannomas 2, 4
Hearing recovery does not predict whether hearing loss is tumor-related 2
Associated events, such as barotrauma or viral infection, are present in approximately one-third of vestibular schwannoma patients, making these unreliable exclusion criteria 2, 4

The American Academy of Otolaryngology-Head and Neck Surgery recommends MRI of the brain, brainstem, and internal auditory canals with gadolinium as the most sensitive test for detecting retrocochlear pathology 1, 6, 7
Sensitivity of MRI for vestibular schwannoma detection is extremely high 8, 9
Additional diagnostic value of MRI includes identifying other causes such as cochlear inflammation, multiple sclerosis, and small vessel cerebral ischemia 8, 9
Overall pathogenic MRI abnormality rate is 7-13.75% in sudden sensorineural hearing loss 8
Vestibular schwannoma prevalence is 2.7-10.2% in patients presenting with sudden hearing loss 2, 3, 5

Auditory Brainstem Response (ABR) may be used when MRI is contraindicated, but has significant limitations, including missing 20% of intracanalicular vestibular schwannomas 1, 6
ABR is highly sensitive only for tumors >1 cm 10, 8
ABR cannot be performed when hearing loss exceeds 80 dB in the 2000-4000 Hz range 10, 8, 9
Serial audiometry is acceptable only in highly selected patients, with explicit counseling about delayed diagnosis risk 10, 8, 9

Early tumor identification allows for optimal shared decision-making and potentially better preservation of hearing and facial nerve function 1, 6
Smaller tumors at diagnosis are associated with better treatment outcomes regardless of management strategy 1
Treatment differs for vestibular schwannoma-related hearing loss, with systemic steroids potentially used, but intratympanic steroids and hyperbaric oxygen not indicated 1, 6